Interim Shareholders
Report 2025
31 December 2024




2025 Half Year Results
                                                                             F I N A N C I A L H I G H L I G H TS
Dear Shareholders,

We are pleased to report EBOS delivered strong underlying growth1            Underlying Results2                    inc. CWA ex. CWA
for the first half of the 2025 financial year reflecting the strength of
our diversified business model.                                              $6.0 billion revenue                   -9.0%     +9.5%

We are also on-track to achieve our guidance for the full year               $291 million EBITDA                    -7.1%     +7.1%
following the Group’s half year performance. This result reflects the        $131 million net profit after tax
execution of our near-term strategies to drive revenue growth, cost
efficiencies and strategic acquisitions. The statutory results are
down on the prior corresponding period reflecting the loss of the
CWA distribution contract. However, the Group increased Underlying
EBITDA by 7.1%1 excluding the CWA contract.                                U N D E R LY I N G E B I T DA
To provide shareholders with a like-for-like comparison to the
                                                                             184.1          207.7           289.2     313.2     291.1
prior corresponding period, where applicable, this report includes
comparisons against underlying earnings exclusive of the estimated
revenue and earnings from the CWA contract.




Key Highlights




$6.0b                                        $131m
                                                                             2020           2021            2022      2023       2024

                                                                           Six months to 31 December ($millions)
revenue                                      underlying NPAT
                                                                           INTERIM DIVIDEND PER SHARE

                                                                              42.5           47.0           53.0      57.0       57.0




NZ 57.0c 11,881
interim dividend per share                   shareholders




                                                                             FY21           FY22            FY23     FY24        FY25



All amounts are denoted in Australian dollars unless otherwise stated.     Six months to 31 December (NZ cents)
                                                                                                                                        1
                                                                                                                Interim Shareholders Report 2025


Half-Year Highlights2                                                           S EG M E N T R E S U LTS

• Revenue of $6.0 billion (up 9.5%1)
                                                                                Healthcare
• Underlying EBITDA of $291 million (up 7.1%1)
• Underlying NPAT of $131 million
• Underlying EPS of 67.5 cents
• Interim dividend declared of NZ 57.0 cents per share
                                                                                        $5.7b                          $250m
   (maintained at H1 FY24 level)                                                                                      underlying
                                                                                        revenue
• Strong progress made on the near-term growth strategies:
                                                                                        (+9.7%1)                       EBITDA
 >U
   nderlying EBITDA growth for the Healthcare and Animal Care                                                         (+7.0%1)
  segments of 7.0%1 and 7.2% respectively
 > Approximately $100m revenue from new pharmacy wholesale
    customers ($450m+ annualised)
 > $15m cost savings achieved
                                                                                Animal Care
 > Three investments completed in the Medical Technology business
   in Southeast Asia3
• EBOS reiterates its guidance that the Group expects to generate
   Underlying EBITDA between $575 - $600 million in FY25

Healthcare summary
                                                                                       $304m                            $59m
Our Healthcare segment generated revenue of $5.7 billion and
                                                                                        revenue                       underlying
Underlying EBITDA of $250 million, an increase of 9.7% and 7.0%1                        (+6.3%)                        EBITDA
respectively on the prior corresponding period. This performance                                                       (+7.2%4)
was driven by organic growth and strong performances across the
Community Pharmacy 1, TerryWhite Chemmart (TWC) and Institutional
Healthcare businesses.
                                                                              As a result, overall Contract Logistics Gross Operating Revenue was in-
In Australia, Healthcare revenue was $4.4 billion and Underlying              line with the prior corresponding period.
EBITDA was $200 million, an increase of 11.8% and 6.6% respectively 1
                                                                              Animal Care summary
led by Community Pharmacy and Institutional Healthcare. In New
Zealand & Southeast Asia, Healthcare revenue was $1.3 billion and             Our Animal Care segment generated revenue of $304 million and
Underlying EBITDA was $51 million, representing growth of 2.8% and            Underlying EBITDA of $59 million, an increase of 6.3% and 7.2%
8.5% respectively, primarily driven by double-digit EBITDA growth in          respectively on the prior corresponding period. Animal Care segment
our Transmedic business in Southeast Asia and growth in New Zealand,          growth was driven by the strong performance of the branded business.
excluding COVID-19 related products.
                                                                              The branded business grew revenue by 7.6%, driven by strong
Community Pharmacy revenue was $3.1 billion (up 12.2% 1), driven by           performances from Black Hawk and VitaPet which have continued to
approximately $100m of revenue from new wholesale customers in                either grow or maintain share leadership. In addition, our Superior Pet
H1 FY25 ($450m+ annualised), growth from existing pharmacy wholesale          Food business performed well, with growth in dog roll products and bulk
customers, TWC’s continued sales growth and store expansion and               treats. The branded business also grew revenue from new products
accelerating sales of GLP-1 medicines, as supply becomes increasing           launched in 2024. This growth was partially offset by softer demand in
available. The Community Pharmacy business made excellent progress            discretionary categories such as accessories.
in adjusting to the lower sales volumes with a number of initiatives
implemented to ensure our productivity measures were in line with             Animal Care’s wholesale business, Lyppard, returned to steady growth
expectations. Further improvements are expected in the second half and        with revenue growth for the period of 4.8%, due to higher trading in vet
FY26 as we adjust our operations to the lower volumes. Pleasingly, the        groups combined with easing of cat vaccine supply issues.
First Pharmaceutical Wholesaler Agreement was signed in December
                                                                              Cash Flow, Return on Capital Employed, Net Debt
2024 and provides for a modest funding increase from H2 FY25 and a
                                                                              and Net Finance Costs
further increase from FY27.
                                                                              The Group generated solid underlying operating cash flow of
The TWC network reached 616 stores in the half, adding 52 stores in the
                                                                              $205 million, up $90 million compared to the prior corresponding
last year and grew network sales by 11.0% and like-for-like sales by 9.3%.
                                                                              period, reflecting an improvement in net working capital.
Institutional Healthcare revenue increased by $191 million (up 9.7%)
                                                                              Return on Capital Employed (ROCE), excluding the CWA contract,
and Gross Operating Revenue increased by $25 million (up 8.3%).
                                                                              was 13.3%. As previously announced, ROCE has been reset
Medicines and consumables revenue grew by 10.5%, driven predominantly
                                                                              with the conclusion of the CWA contract. On a like-for-like basis,
by Symbion Hospitals’ sales of high value specialty medicines. Medical
                                                                              ROCE marginally improved compared to June 2024.
Technology delivered revenue growth of 5.5% driven by strong growth
in allografts, implants and orthopaedics and double-digit growth in           The Net Debt : EBITDA ratio at 31 December 2024 was 2.07x (2.06x as at
Southeast Asia. Medical Technology growth was partially offset by supply      31 December 2023). During the period, EBOS refinanced its corporate
issues in the spine channel, which are expected to ease in the second half,   debt facilities, extending the weighted average maturity to 3.3 years
and capital sales being impacted by reduced hospital demand.                  (FY24: 1.6 years) and increasing available funds by $150 million.
Three investments were completed in the Medical Technology business in        Net Finance Costs increased to $51 million primarily due to lease
Southeast Asia and are consistent with EBOS’ strategy of growing in that      interest costs associated with new distribution centres and higher
region3. The Group recently increased its shareholding in Transmedic from
                                                                              interest rates.
90% to 100% and completed two bolt-on acquisitions, one in Malaysia
and one in the Philippines, which strengthen Medical Technology’s             Sustainability and Community
presence in the orthopaedics segment in those countries. In aggregate,        We remain committed to implementing environmentally responsible
we have deployed approximately $70 million for these three investments.       practices and initiatives across our business.
Our Contract Logistics business in Australia continues to generate
                                                                              While New Zealand already utilises renewable energy, we remain on
growth through new and existing principals, enabled by the investment
                                                                              track to self-generate solar power equivalent to our forecast Australian
in new warehouse capacity. In New Zealand, the Contract Logistics
                                                                              electricity consumption by FY27. In October 2024, we released our
business experienced a reduction in first half Gross Operating Revenue
                                                                              first Climate Statement which can be found at www.ebosgroup.com/
due to a fall in demand for the storage and servicing of COVID-19
                                                                              sustainability/climate-statement.
related products.
                                                                                                                                                         2
                                                                                                                                                        Interim Shareholders Report 2025



S EG M E N T OV E RV I E W

Healthcare                                                                                               Animal Care

      161.3            185.2            255.0            275.5           250.5                               33.9             38.8             51.0             55.4             59.3
                                                                                                                                                                                          55.4




      2020             2021             2022             2023             2024                              2020              2021             2022             2023             2024

Underlying EBITDA                                                                                        Underlying EBITDA
Six months to 31 December ($millions)                                                                    Six months to 31 December ($millions)



Animal Care has begun transitioning its VitaPet Snacks and Treats                                        appointed as an independent non-executive director, effective
ranges into 100% recyclable packaging. This transition will take place                                   1 January 2025 and 1 February 2025 respectively. The appointments are
throughout 2025 as we gradually introduce the new packaging into                                         consistent with EBOS’ Board succession planning. EBOS has appointed
retail outlets.                                                                                          five new directors since July 2021 with a diverse mix of skills. The Board
                                                                                                         is now comprised of seven directors, of which six are independent.
Cyber security remains a priority for the Group. We continued to
implement a comprehensive cyber security uplift program to further                                       Interim Dividend
enhance security in line with evolving threats. We also achieved ISO
                                                                                                         The Directors declared an interim dividend of NZ 57.0 cents per share,
27001 cyber security certification for an additional three business units.
                                                                                                         maintained at the H1 FY24 level, reflecting the Board’s confidence in
We introduced Executive Safety Leadership Walks in our distribution                                      the future growth of the Group. This implies a dividend payout ratio of
centres to drive proactive engagement, increase visibility and improve                                   77.3%5 on an underlying basis.
safety outcomes. In addition, we launched the EBOS Life Savers
                                                                                                         The record date for the dividend is 28 February 2025 and the dividend
initiative, which outlines critical controls to reduce the risk of significant
                                                                                                         will be paid on 21 March 2025. The dividend will be imputed to 25% for
injury or harm to our employees during high-risk activities.
                                                                                                         New Zealand tax resident shareholders and fully franked for Australian
EBOS continues to collaborate with community partners across New                                         tax resident shareholders.
Zealand and Australia who align with our purpose ‘Advance opportunities
                                                                                                         Outlook
to enrich lives’. Our Group and employees continue to support
organisations including Ovarian Cancer Australia, Guide Dogs Australia,                                  EBOS is pleased with the strong underlying earnings growth1 in the first
BackTrack, LandSAR, FightMND, Cerebral Palsy Alliance and others.                                        half of FY25, driven by both organic growth and acquisitions.

Further detail on our ESG Program can be found at                                                        EBOS has demonstrated resilience and delivered underlying growth1
www.ebosgroup.com/sustainability.                                                                        as we adapt positively to changing market dynamics, reflecting the
                                                                                                         defensive and diverse nature of the Group.
CEO Succession
                                                                                                         EBOS reiterates its guidance that the Group expects to generate
As separately announced, John Cullity will be retiring as CEO, effective
                                                                                                         Underlying EBITDA between $575 – $600 million in FY25. This implies
30 June 2025, and Mr Adam Hall will commence as CEO on 1 July 2025.
                                                                                                         growth of approximately 5-10% compared to the prior year 1. H1 FY25
Adam Hall is a highly accomplished global executive with a strong                                        Underlying EBITDA growth of 7.1%1 is supportive of this guidance.
track record in strategic growth, mergers and acquisitions and
                                                                                                         The Group continues to explore an active pipeline of M&A opportunities.
operational excellence. Most recently, as Group Executive & President
– Asia for Orica Limited, he successfully led significant growth in                                      EBOS employs over 5,200 people and we acknowledge them for their
earnings and scale, while driving innovation and efficiency.                                             extraordinary efforts and unwavering commitment to the communities
                                                                                                         we serve across New Zealand, Australia and Southeast Asia.
The Chair and Board express their gratitude to John for his
outstanding leadership, which has been a key driver of EBOS’ strong                                      We thank all our shareholders for their ongoing support.
growth over his seven years as CEO and look forward to welcoming
Adam to the EBOS team.

Board Renewal
Consistent with EBOS’ Board renewal process, Matt Muscio was
appointed as a non-executive director and Coline McConville was                                          Liz Coutts                                           John Cullity
                                                                                                         Chair of the Board                                   Chief Executive Officer



1
    Growth is H1 FY25 Underlying compared to H1 FY24 Underlying when normalised to exclude the Chemist Warehouse Australia (CWA) contract.
2
    Underlying earnings for both the 31 December 2024 and 31 December 2023 periods exclude one-off M&A transaction costs and the amortisation (non-cash) expense attributable
     to the LifeHealthcare acquisition purchase price accounting (PPA) of finite life intangible assets. Underlying earnings for the 31 December 2024 period also exclude non-recurring
     restructuring and site transition costs.
3
    Includes one acquisition that was previously announced at the FY24 results and was completed in July 2024, and one investment that was completed in January 2025.
4
    Underlying earnings for the 31 December 2023 period excludes one-off M&A costs.
5
    Dividend payout ratio is based on an underlying basis on a NZD:AUD average exchange rate of 0.912.
                                                                                                                                                                                                 3
